ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

13,569Medicare Part D Prescriptions Filled, Including Refills

Rank: 419 out of 6645

$627K Total Retail Price of All Prescriptions

Rank: 780 out of 6645

466 Patients Receiving at Least One Drug in Part D
72%Patients 65 Years and Older
70% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in California
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 466 patients filled at least one prescription for a schedule two drug, compared to an average of 3%.

Schedule Three
Controlled Substances

26% of this provider’s 466 patients filled at least one prescription for a schedule three drug, compared to an average of 13%.

Risky Drugs to Seniors

1% of this provider’s 10,018 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$46 was the average price of a prescription from this provider, compared to $64 among peers.

Prescriptions per Patient

29 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in California
HYDROCODONE-ACETAMINOPHEN 623 370 S3 1 5
SIMVASTATIN 566 411 2 1
LEVOTHYROXINE SODIUM 557 460 3 4
LISINOPRIL 529 419 4 3
AMLODIPINE BESYLATE 407 336 5 2
OMEPRAZOLE 327 209 6 6
ATENOLOL 322 264 7 8
GLIPIZIDE 318 240 8 23
METFORMIN HCL 314 241 9 7
WARFARIN SODIUM 283 265 10 16
FUROSEMIDE 236 194 11 11
FAMOTIDINE 215 203 12 33
RANITIDINE HCL 210 152 13 51
METOPROLOL TARTRATE 209 192 14 13
GABAPENTIN 205 91 15 18
TRAZODONE HCL 181 146 16 60
SERTRALINE HCL 171 116 17 43
FLUOXETINE HCL 154 86 18 63
IBUPROFEN 149 44 19 42
HYDROCHLOROTHIAZIDE 146 123 20 9
BENAZEPRIL HCL 138 101 21 21
DIVALPROEX SODIUM 133 116 22 113
DONEPEZIL HCL 131 131 23 27
ALENDRONATE SODIUM 130 123 24 14
CITALOPRAM HBR 124 75 25 35
CARISOPRODOL 116 16 R 26 94
QUETIAPINE FUMARATE 116 95 26 101
LOVASTATIN 116 107 26 15
RISPERIDONE 115 84 29 93
PANTOPRAZOLE SODIUM 114 85 30 29
MIRTAZAPINE 112 103 31 70
CARVEDILOL 111 76 32 25
TRAMADOL HCL 105 61 33 30
OLANZAPINE 100 79 34 140
ZOLPIDEM TARTRATE 98 66 35 17
ENALAPRIL MALEATE 89 58 36 75
CEPHALEXIN 87 68 37 111
PROAIR HFA 86 56 38 32
CLOPIDOGREL 81 70 39 36
PAROXETINE HCL 78 59 40 72
TAMSULOSIN HCL 78 63 40 22
FENOFIBRATE 73 44 42 74
POTASSIUM CHLORIDE 71 60 43 28
ADVAIR DISKUS 70 66 44 45
JANUVIA 69 67 45 38
PREDNISONE 68 63 46 57
LOSARTAN POTASSIUM 67 66 47 12
ATORVASTATIN CALCIUM 65 40 48 10
NOVOLIN R 63 41 49 142
CLONIDINE HCL 61 38 50 56
LANTUS 61 44 50 50
PLAVIX 60 43 52 49
GEMFIBROZIL 60 34 52 96
SEROQUEL 58 47 54 208
TRIAMTERENE-HYDROCHLOROTHIAZID 58 41 54 143
PHENYTOIN SODIUM EXTENDED 57 50 56 172
KLOR-CON M10 55 48 57 276
GLYBURIDE 54 36 R 58 58
VENTOLIN HFA 53 17 59 146
KLOR-CON M20 53 44 59 203
SPIRIVA 52 52 61 65
VERAPAMIL ER 50 47 62 154
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 1, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.